Asset Details
Do you wish to reserve the book?
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Do you wish to request the book?
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
2005
Overview
When administered to patients for pain control after coronary-artery bypass surgery, valdecoxib and its intravenous prodrug, parecoxib, were found to be associated with an increased risk of cardiovascular thromboembolic events. These findings add to the growing concern that the use of COX-2 inhibitors increases the risk of cardiovascular events, particularly in persons who are at risk for such events.
When administered to patients for pain control after coronary-artery bypass surgery, valdecoxib and its intravenous prodrug, parecoxib, were found to be associated with an increased risk of cardiovascular thromboembolic events.
Nonsteroidal antiinflammatory drugs (NSAIDs) are established pharmacologic tools for treating postoperative pain. However, concern about the possibility of gastric ulceration, renal injury, and bleeding has limited the use of NSAIDs in some surgical and critical care settings.
1
The selective cyclooxygenase-2 (COX-2) inhibitor valdecoxib (Bextra, Pfizer) and its intravenous prodrug parecoxib (Dynastat, Pfizer) were found to exert significant opioid-sparing effects after dental, gynecologic, orthopedic, and other noncardiac surgical procedures, apparently without causing serious adverse effects.
2
–
5
Similar efficacy was demonstrated in a study of parecoxib and valdecoxib in patients recovering from coronary-artery bypass grafting (CABG).
6
In that study, however, these drugs . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Cardiovascular Diseases - chemically induced
/ Cardiovascular Diseases - epidemiology
/ Cardiovascular Diseases - mortality
/ Coronary Artery Bypass - mortality
/ Cyclooxygenase Inhibitors - adverse effects
/ Cyclooxygenase Inhibitors - therapeutic use
/ Female
/ Humans
/ Isoxazoles - adverse effects
/ Isoxazoles - therapeutic use
/ Male
/ Pain
/ Pain, Postoperative - drug therapy
